Tag: psilocybin

20,000 people in Oregon have now received legal psilocybin therapy, and the outcomes are overwhelmingly positive

In 2020, Oregon became the first US state to approve the use of psilocybin therapy, and new data suggests that the psychedelic drug is being used to great effect at state-regulated clinics.

Among those accessing legal psilocybin therapy in Oregon, the majority report significant improvements in mental health, wellbeing, and life satisfaction in the three months after treatment, with very few patients experiencing adverse events.

Since 2023, more than 20,000 people have legally accessed psilocybin therapy in Oregon, with 26 treatment centers currently holding licenses to administer the drug. Using data from 24 of these clinics, researchers analyzed the experiences and outcomes of 346 patients, all of whom underwent treatment between November 2024 and March 2026.

“Most participants were highly satisfied with their psilocybin experience, would recommend their licensed service center and facilitator, felt the experience was beneficial, and that their goals for seeking services had been met,” write the study authors.

One month after taking the drug, 92.2 percent of individuals stated that they had benefited from their treatment, with 58.6 percent ranking the experience among the 10 most meaningful events of their life.

Prior to treatment, 63 percent of participants said they were satisfied with their lives, yet this figure rose to 82.3 percent three months after taking psilocybin. On average, scores on a standard test that measures wellbeing rose from 22.1 at baseline to 25.3 at the three-month follow-up.

Keep reading

Major VA study to examine effectiveness of psilocybin on depression, PTSD

The Department of Veterans Affairs is launching research to determine whether psilocybin — the psychoactive ingredient in “magic mushrooms” — can be used safely and effectively to address veterans’ treatment-resistant depression and post-traumatic stress disorder.

The trial, known as the Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression,” or PIVOT, study aims to include at least 240 veterans, all of whom have difficult-to-treat major depressive disorder and some who also have PTSD.

The study will take place at five VA medical centers through June 2031 and will assess patients’ levels of depression before and after treatment, side effects and overall response among participants.

“Far too many veterans are living with mental health conditions that don’t respond to available treatments,” VA Secretary Doug Collinssaid in a statement. “Under President [Donald] Trump, VA is pursuing all avenues to evaluate new treatments and offer meaningful relief for those who have worn the uniform. This clinical trial reflects another step toward this goal.”

Last month, researchers with Ohio State University’s Center for Psychedelic Drug Research and Education published the findings of a small, 12-person study on the safety of using psilocybin to treat severe PTSD in veterans.

After receiving eight hours of psychotherapy and two doses of synthetic psilocybin and integrative therapy, nine participants, or 75%, no longer met the clinical criteria for having PTSD.

According to the research, published July 30 in Communications Medicine, participants showed no serious adverse effects, including suicidal ideation or behavior. Non-serious side effects included headache, anxiety and dizziness.

“For a population with severe treatment-resistant PTSD, these results are striking,” said Stacey Armstrong, associate director and senior researcher at the center.

The PIVOT study will involve veterans with major depressive disorder who have not responded to current treatments, including those with or without a diagnosis of PTSD. In the double-blind, randomized trial, veterans will receive one dose of psilocybin or a placebo, along with therapeutic support. They will receive a second dose one month later, also with support, and will be evaluated two to four weeks following each session.

They also will receive follow-up six months after their participation.

Keep reading

The Woman Who Came Back: What One Dose of Psilocybin Revealed About the Self We Thought Alzheimer’s Had Erased

In 1971, psilocybin was declared to have “no accepted medical use.” In 2026, it appeared to reach into the ruins of an advanced Alzheimer’s brain and switch a human being back on.

Not permanently. Not by reversing the disease. But for days and weeks—long enough for her family to have her back, long enough to force a question that mainstream neurology has spent decades trying not to ask.

I’ve reported before on psilocybin as a longevity molecule—the Emory findings showing psilocin extending human cellular lifespan by up to 57%, aged mice surviving 60% better, telomeres preserved, neuroplasticity switched on. In that piece I listed Alzheimer’s among the “neurological frontiers” where this ancient fungal ally was beginning to be tested. I did not expect the frontier to move this fast.

The paper is titled, in the careful language of clinical medicine, “Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration.” Behind that title is a woman.

She was an octogenarian Japanese-American woman living under continuous family and caregiver supervision. Her Alzheimer’s had been progressing for roughly ten years. For the last five, her speech had collapsed into monosyllables. She was chronically incontinent. She could not dress herself, could not walk unaided, struggled to swallow, and had lost most of her capacity for spontaneous interaction. Her affect was flat. By every conventional measure, she was in the late, “irreversible” stage of the disease—the stage where medicine offers comfort and little else.

Under supervision, she was given a single oral dose of 5 grams of psilocybin-containing mushrooms (the “Enigma” strain)—a deliberately high dose, well above what modern psychiatric trials typically use.

The acute phase was not gentle, and I want to be honest about that up front. She showed signs of autonomic overdrive: clinically suspected hyperthermia, profuse sweating, and a long, deep, sleep-like state. This is not a small detail, and I’ll come back to why it matters enormously.

Then, approximately nineteen hours later, at 3:30 in the morning, she woke up and began to talk. Not in fragments. She spoke about her own life—autobiographical, spontaneous, coherent—for something on the order of four hours.

Keep reading

Advanced Alzheimer’s successfully treated with psilocybin, a recent case study says

A newly published case report in Frontiers in Neuroscience describes a remarkable and unexpected clinical response in an 80-year-old woman with advanced Alzheimer’s disease following a single high-dose psilocybin intervention.

The patient had lived with Alzheimer’s disease for approximately 10 years and experienced severe functional decline over the preceding five years. According to the report, she had become largely monosyllabic, demonstrated profound cognitive impairment, chronic urinary incontinence, impaired mobility, dysphagia, executive dysfunction and severe reduction in spontaneous communication and emotional engagement.

After receiving a single 5g oral dose of psilocybin-containing mushrooms (Enigma strain), the patient reportedly experienced rapid and sustained functional improvement across multiple domains.

During the acute phase, the patient entered a prolonged deep sleep-like state accompanied by profuse sweating and clinically suspected hyperthermia.

Then, approximately 19 hours later, something unexpected occurred.

The patient spontaneously awakened and began speaking for hours, engaging in autobiographical conversation and recalling memories that had not been expressed in years.

Over the following days, her family reported meaningful improvements in:

  • Speech and communication.
  • Memory and contextual recognition.
  • Walking and mobility.
  • Emotional connection and social engagement.
  • Bladder control, after years of chronic urinary incontinence.

Keep reading

A Single Dose Of Psilocybin Can Lead To ‘Rapid’ And ‘Long-Lasting’ Improvements In Depression, Study Indicates

A single dose of psilocybin, coupled with therapy sessions, significantly improved symptoms of depression within days and lasting for a period of months, according to a first-of-its-kind study out of Sweden that was published by the American Medical Association.

Researchers at Karolinska Institutet and the Brain Stimulation Clinic in Stockholm conducted the phase 2 randomized clinical trial, which involved 35 participants with moderate-t0-severe depression who received either a 25 milligram dose of psilocybin or a placebo of niacin.

For the study, published in JAMA Psychiatry last week, patients also underwent five psychotherapy sessions to supplement the psychedelic or placebo experience.

The psilocybin cohort, on average, showed clinically observable improvement in their symptoms compared to the placebo group at day 8.

“This finding implies that psilocybin can be an option to standard treatments when rapid symptom relief is important,” the paper says.

By the sixth week of the trial, 53 percent of the psilocybin cohort were considered to be in remission for depression, while just 6 percent of the placebo group said the same by that point.

However, researchers found that the overall effect seemed to subside after a year.

”Our results suggest that psilocybin can provide rapid, clinically meaningful improvement in depression and may serve as an alternative to standard treatment when fast symptom reduction is important,” lead study author Hampus Yngwe said in a press release.

Keep reading

Psilocybin Helps People Quit Cigarettes More Effectively Than Nicotine Patches Do, American Medical Association-Published Study Shows

Just one dose of psilocybin combined with therapy is associated with “significantly increased long-term abstinence” from cigarettes compared to nicotine patches, according to a new study published by the American Medical Association (AMA) that indicates the psychedelic “holds potential in the treatment of tobacco use disorder.”

Researchers at Johns Hopkins University School of Medicine and the University of Alabama at Birmingham conducted the study, published in JAMA Substance Use and Addiction, finding more evidence about the therapeutic potential of single-dose psilocybin in tandem with cognitive behavioral therapy (CBT).

The randomized clinical trial of cigarette smokers involved administering one high dose (30mg/70kg) of psilocybin or 8-10 weeks of Food and Drug Administration- (FDA) approved nicotine patch treatment, with both groups participating in a 13-week CBT program for smoking cessation.

“A total of 82 psychiatrically healthy adult smokers participated in the study, with 68 (82.9 percent) completing the 6-month follow-up,” the paper says. “At 6-month follow-up, 17 participants receiving psilocybin (40.5 percent) exhibited biochemically verified prolonged abstinence compared with 4 participants using the nicotine patch (10.0 percent), and 22 participants receiving psilocybin (52.4 percent) exhibited biochemically verified 7-day point prevalence abstinence compared with 10 participants using the nicotine patch (25.0 percent).”

Put another way, smokers who received psilocybin had more than six times greater odds of prolonged abstinence and more than three times greater odds of seven-day abstinence compared to the nicotine patch participants.

“In this pilot randomized clinical trial, one dose of psilocybin with manualized CBT significantly increased long-term abstinence compared with nicotine patch treatment with CBT,” the authors said. “Psilocybin abstinence rates were higher than typical treatments, suggesting promise for tobacco smoking cessation.”

Keep reading

Psilocybin Shows Potential to Improve Long-Term Effects of Repetitive Brain Injuries Linked to Intimate Partner Violence

The research involved teams from the University of Victoria, Monash University, and Vancouver Island University.

The study examined a rat model designed to mimic the types of injuries commonly reported in IPV survivors: repeated mild traumatic brain injury and short episodes of non-fatal strangulation. Female rats received daily head impacts followed by 90-second strangulation events for five consecutive days, then were allowed a 16-week recovery period to mirror the chronic symptoms often seen in humans.

After the recovery period, the animals were given either a single dose of psilocybin (1 mg/kg) or saline. Those that received psilocybin showed notable improvements. Anxiety-like behaviors normalized in the elevated plus-maze, measures of motivation improved through increased sucrose preference, and cognitive performance strengthened in both spatial-memory and reversal-learning tests. These benefits disappeared when rats were pre-treated with a 5-HT2A receptor–blocking compound, indicating that psilocybin’s effects were driven by this serotonin receptor.

The brain analysis aligned with the behavioral results. Injured rats that received saline had more activated microglia—an indicator of neuroinflammation—in the dorsal hippocampus, as well as fewer reelin-positive cells linked to neuroplasticity. Those alterations were not present in the psilocybin-treated group.

Taken together, the findings suggest that psilocybin’s antidepressant-like, pro-cognitive, and anti-inflammatory actions may help counter long-term effects of repetitive IPV-related brain injury, and that the 5-HT2A receptor plays a key role in those benefits.

Keep reading

Psilocybin therapy linked to reduced suicidal thoughts in people with psychiatric disorders

A new study published in Therapeutic Advances in Psychopharmacology provides evidence that psilocybin therapy may reduce suicidal ideation in adults with psychiatric conditions. The findings come from a systematic review and meta-analysis of clinical trials and suggest that the psychedelic compound, when paired with psychological support, may have a modest but measurable impact on decreasing thoughts of suicide. Although suicide attempts and deaths were not observed in these trials, the results point to the possibility that psilocybin could play a role in mental health treatment strategies aimed at reducing suicide risk.

Psilocybin is a naturally occurring psychedelic compound found in certain mushrooms, sometimes called “magic mushrooms.” It affects the brain by stimulating serotonin receptors, particularly one known to play a role in mood regulation and emotional processing. When administered in controlled clinical settings alongside therapy, psilocybin has been shown to help relieve symptoms of depression, anxiety, and some forms of addiction.

Interest in psilocybin as a therapeutic agent has grown rapidly in recent years, especially for people who do not respond to standard treatments like antidepressants or talk therapy. Some smaller studies have suggested that psilocybin therapy might also reduce suicidal ideation, a symptom common in many psychiatric conditions.

Given suicide’s widespread toll on public health, researchers wanted to evaluate whether these early signs held up across multiple trials. To do this, they examined all available randomized controlled trials that reported on suicide-related outcomes in people undergoing psilocybin therapy.

“I was inspired to investigate the usage of psilocybin therapy to help treat my patients who suffer from treatment resistant depression. As I was reading the latest clinical trials at the time, there were some reports of increasing suicidal ideation. Increasing suicidal ideation would be a risk in this vulnerable population. When I was reviewing the literature, there was not much synthesized evidence which inspired me to pursue this study,” explained study author Stanley Wong, a general psychiatry resident at the University of Toronto.

To assess the potential impact of psilocybin therapy on suicidal ideation and behaviors, the research team carried out a systematic review and meta-analysis. A systematic review collects and evaluates all relevant studies on a specific topic using a structured and transparent process. A meta-analysis goes a step further by statistically combining results from multiple studies to estimate an overall effect. This method is often used in medicine to determine how well a treatment works by comparing evidence across different settings, sample sizes, and trial designs.

Keep reading

From trips to treatments: how psychedelics could revolutionise anti-inflammatory medicine

Once synonymous with hippies and hallucinatory experiences, psychedelic drugs are now being explored for their medical potential. The stigma of that era resulted in research being suppressed by drug laws, yet with mental health treatments hitting limits, scientists have returned to this controversial corner of medicine.

Substances like psilocybin (found in magic mushrooms) and ayahuasca are now being taken seriously by scientists and doctors, not for the visions they induce, but for the healing potential they possess.

Initially, this focused on treating mental health conditions like depression, where currently prescribed drugs only help a minority of patients. But these investigations have now expanded to include diseases driven by inflammation, which psychedelic drugs may help reduce by calming down the immune system.

In both human cells grown in laboratory dishes and animal studies, psychedelic drugs like DMT, LSD, and a compound called (R)-DOI can block the release of inflammatory molecules called cytokines. These protein molecules fuel conditions like rheumatoid arthritis, asthma and even depression, as well as increasing brain damage following traumatic brain injury.

Advantage over steroids

But these drugs have a considerable advantage over typical anti-inflammatory medications like steroid drugs because psychedelics appear to work without suppressing healthy immune function, which is a major problem with steroids.

Significantly, these laboratory findings are beginning to be confirmed in studies in humans. Evidence is growing that psychedelics could hold the key to managing inflammation, one of the body’s central drivers of many chronic diseases, including depression, arthritis and heart conditions.

Take psilocybin, the active ingredient in magic mushrooms. In a study involving 60 healthy participants, just one dose was enough to significantly lower levels of two key inflammatory molecules – TNF-alpha and IL-6 – over the following week.

However, not all studies have shown the same clear results. Some only had a few participants and others were complicated by the fact that some participants had previous drug experience, which could affect the results.

One big challenge with studying psychedelics in medical research is that it’s very hard to hide who got the real drug and who got a placebo. When someone has a strong psychedelic experience, it’s obvious they didn’t just take a sugar pill.

Keep reading

A single psilocybin dose rapidly reverses chronic pain and depression in mice, study finds

In a stunning breakthrough that challenges the very foundations of chronic pain treatment, researchers have discovered that a single dose of a natural compound can rapidly reverse both physical suffering and the depression that accompanies it.

Scientists at the University of Pennsylvania found that psilocybin, the active ingredient in so-called magic mushrooms, provided lasting relief from chronic pain and depression-like symptoms in mice by calming overactive brain circuits. This research, published in the journal Nature Neuroscience, offers a radical new pathway for treating the millions who suffer from the intertwined conditions of chronic pain and mental anguish.

For the 50 million Americans living with chronic pain, this discovery represents a beacon of hope beyond the dangerous and often ineffective world of opioid pharmaceuticals. The study reveals that chronic pain does not merely hurt the body but actively rewires the brain, creating a cycle of psychological suffering that intensifies the original physical pain. This vicious cycle has long been exploited by pharmaceutical companies pushing addictive painkillers that fail to address the root cause of the problem.

The research team created two types of lasting pain in mice, some with nerve damage and others with severe inflammation. Both groups developed hypersensitivity to touch and displayed behaviors mirroring profound anxiety and depression in humans. Brain imaging identified the culprit: a region called the anterior cingulate cortex, which processes both the emotional experience of pain and regulates mood, had essentially malfunctioned. Nerve cells in this area were firing 40% more than normal and refused to calm down.

Keep reading